Abstract
Signalling through the ERBB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs. Because of its inherent complexity, it is useful to envision ERBB signalling as a bow-tie-configured, evolvable network, which shares modularity, redundancy and control circuits with robust biological and engineered systems. Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation.
| Original language | English |
|---|---|
| Pages (from-to) | 505-516 |
| Number of pages | 12 |
| Journal | Nature Reviews Molecular Cell Biology |
| Volume | 7 |
| Issue number | 7 |
| DOIs | |
| State | Published - 17 Jul 2006 |
| Externally published | Yes |
Bibliographical note
Funding Information:We thank B. Kholodenko, S. H. Wiley, M. Hatakeyama and P. De-Meyts for insightful comments. Our laboratory is supported by research grants from the National Cancer Institute, the Israel Science Foundation, the Israel Cancer Research Fund, the Prostate Cancer Foundation and the German-Israel Foundation. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.
